The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure

UTSePress Research/Manakin Repository

Search UTSePress Research

Advanced Search


My Account

Show simple item record Newton, Phillip en_US Davidson, Patricia en_US Krum, Henry en_US Ollerton, Richard en_US Macdonald, Peter en_US
dc.contributor.editor en_US 2012-10-12T03:34:32Z 2012-10-12T03:34:32Z 2012 en_US
dc.identifier 2011003710 en_US
dc.identifier.citation Newton Phillip et al. 2012, 'The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure', Elsevier, vol. 21, no. 5, pp. 260-266. en_US
dc.identifier.issn 1443-9506 en_US
dc.identifier.other C1 en_US
dc.description.abstract Purpose: To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population. In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure under-going right heart catheterisation were randomised to receive either 40 mg (4 ml) of nebulised frusemide or 4 ml of normal saline. Following inhalation of the study medication, subjects pulmonary pressures were recorded every 15 min for 1 h. There were no significant changes in the weighted average time course data of the subjects (n = 32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups. Weighted average pulmonary capillary wedge pressure after 60 min in the frusemide group was 22.5 (SD 6.5) mmHg (n = 14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n = 18), p = 0.55. The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186 ml IQR 137.8-260.8) compared to the placebo group (76 ml IQR 39.0-148.0) p = 0.02. This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects. en_US
dc.language en_US
dc.publisher Elsevier en_US
dc.relation.isbasedon en_US
dc.title The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure en_US
dc.parent Heart Lung and Circulation en_US
dc.journal.volume 21 en_US
dc.journal.number 5 en_US
dc.publocation Australia en_US
dc.identifier.startpage 260 en_US
dc.identifier.endpage 266 en_US FOH.Faculty of Health en_US
dc.conference Verified OK en_US
dc.for 110200 en_US
dc.personcode 111808 en_US
dc.personcode 110950 en_US
dc.personcode 0000069166 en_US
dc.personcode 0000076312 en_US
dc.personcode 117187 en_US
dc.percentage 50 en_US Cardiovascular Medicine and Haematology en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US en_US
dc.location.activity en_US
dc.description.keywords Heart failure; Haemodynamics; Frusemide en_US
dc.staffid 117187 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record